Download
IID509393.pdf 447,98KB
WeightNameValue
1000 Titel
  • A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative Colitis
1000 Autor/in
  1. Radeke, Heinfried |
  2. Stein, Jürgen |
  3. Van Assche, Gert |
  4. Rogler, Gerhard |
  5. Lakatos, Peter L. |
  6. Muellershausen, Florian |
  7. Moulin, Pierre |
  8. Jarvis, Philip |
  9. Colin, Laurence |
  10. Gergely, Peter |
  11. Kruis, Wolfgang |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-08-21
1000 Erschienen in
1000 Quellenangabe
  • 5(4):180-190
1000 Copyrightjahr
  • 2020
1000 Embargo
  • 2021-02-23
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1159/000509393 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7706482/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background and aims!#!KRP203 is a potent oral agonist of the sphingosine-1-phosphate receptor subtype 1 that induces the sequestration of peripheral lymphocytes, thereby potentially reducing the number of activated lymphocytes circulating to the gastrointestinal tract.!##!Methods!#!We conducted a multicentre, double-blind, placebo-controlled, parallel-group, proof-of-concept study to evaluate the efficacy, safety, and tolerability of KRP203 in patients with moderately active 5-aminosalicylate-refractory ulcerative colitis (UC). Patients were randomly assigned to receive 1.2 mg KRP203 or placebo daily for 8 weeks. Primary efficacy variable was clinical remission, defined as partial Mayo Score 0-1 and modified Baron Score 0-1 with rectal bleeding subscore 0.!##!Results!#!KRP203 was safe and well tolerated overall. The most common adverse events (AEs) were gastrointestinal disorders and headache. Importantly, no KRP203-related cardiac AEs were reported. Total peripheral lymphocytes and selectively affected lymphocyte subtypes decreased, causing marked decreases in naive and central memory CD4+ and CD8+ T cells, and also in B cells. Clinical remission occurred in 2/14 (14%) patients under KRP203, compared with 0/8 (0%) under placebo.!##!Conclusions!#!Overall, KRP203 was safe and well tolerated by patients with UC. Importantly, no cardiac AEs were reported. Although KRP203 did not meet the minimum clinically relevant threshold for efficacy, the results may suggest that KRP203 treatment is superior to placebo. However, in this small study population, the difference was insignificant. Based on these data, studies with an improved design and a larger population should be considered.
1000 Sacherschließung
lokal Sphingosine-1-phosphate
lokal Clinical trials
lokal Ulcerative colitis
lokal Research Article
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-4499-2510|https://orcid.org/0000-0003-3558-3341|https://frl.publisso.de/adhoc/uri/VmFuIEFzc2NoZSwgR2VydA==|https://frl.publisso.de/adhoc/uri/Um9nbGVyLCBHZXJoYXJk|https://frl.publisso.de/adhoc/uri/TGFrYXRvcywgUGV0ZXIgTC4=|https://frl.publisso.de/adhoc/uri/TXVlbGxlcnNoYXVzZW4sIEZsb3JpYW4=|https://frl.publisso.de/adhoc/uri/TW91bGluLCBQaWVycmU=|https://frl.publisso.de/adhoc/uri/SmFydmlzLCBQaGlsaXA=|https://frl.publisso.de/adhoc/uri/Q29saW4sIExhdXJlbmNl|https://frl.publisso.de/adhoc/uri/R2VyZ2VseSwgUGV0ZXI=|https://frl.publisso.de/adhoc/uri/S3J1aXMsIFdvbGZnYW5n
1000 Hinweis
  • DeepGreen-ID: 31a31bfc36724114b948a7f50ba7fbdd ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6475054.rdf
1000 Erstellt am 2024-04-11T14:12:31.800+0200
1000 Erstellt von 322
1000 beschreibt frl:6475054
1000 Zuletzt bearbeitet 2024-05-07T12:46:42.996+0200
1000 Objekt bearb. Tue May 07 12:46:42 CEST 2024
1000 Vgl. frl:6475054
1000 Oai Id
  1. oai:frl.publisso.de:frl:6475054 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source